Coherus Launches UDENYCA ONBODY For Pegfilgrastim-cbqv
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences has launched UDENYCA ONBODY, a device for delivering pegfilgrastim-cbqv in just five minutes. The device features a unique, automatic, retractable needle mechanism designed to enhance safety and comfort for cancer patients.
February 21, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus BioSciences' launch of UDENYCA ONBODY, a new device for quick and safe delivery of pegfilgrastim-cbqv, could significantly enhance the company's product offering and patient experience.
The introduction of UDENYCA ONBODY by Coherus BioSciences represents a significant advancement in the delivery of cancer treatment, potentially improving patient compliance and satisfaction. This innovation could lead to increased adoption and sales of UDENYCA, positively impacting CHRS's financial performance in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100